Aravive (ARAV) Competitors $0.04 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. BCDA, BGXX, ATHA, CLDI, AYTU, NERV, PHXM, HCWB, DWTX, and LSBShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include BioCardia (BCDA), Bright Green (BGXX), Athira Pharma (ATHA), Calidi Biotherapeutics (CLDI), Aytu BioPharma (AYTU), Minerva Neurosciences (NERV), PHAXIAM Therapeutics (PHXM), HCW Biologics (HCWB), Dogwood Therapeutics (DWTX), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Aravive vs. Its Competitors BioCardia Bright Green Athira Pharma Calidi Biotherapeutics Aytu BioPharma Minerva Neurosciences PHAXIAM Therapeutics HCW Biologics Dogwood Therapeutics Lakeshore Biopharma BioCardia (NASDAQ:BCDA) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has stronger valuation & earnings, BCDA or ARAV? BioCardia has higher earnings, but lower revenue than Aravive. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$3K3,762.68-$11.57M-$2.33-0.94Aravive$6.99M0.42-$76.32MN/AN/A Is BCDA or ARAV more profitable? Aravive has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. Company Net Margins Return on Equity Return on Assets BioCardia-1,999.77% N/A -208.38% Aravive N/A N/A N/A Does the media prefer BCDA or ARAV? In the previous week, BioCardia had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for BioCardia and 0 mentions for Aravive. BioCardia's average media sentiment score of 1.43 beat Aravive's score of 0.00 indicating that BioCardia is being referred to more favorably in the media. Company Overall Sentiment BioCardia Positive Aravive Neutral Which has more volatility & risk, BCDA or ARAV? BioCardia has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Aravive has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Does the MarketBeat Community prefer BCDA or ARAV? Aravive received 87 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 62.28% of users gave Aravive an outperform vote while only 60.71% of users gave BioCardia an outperform vote. CompanyUnderperformOutperformBioCardiaOutperform Votes1760.71% Underperform Votes1139.29% AraviveOutperform Votes10462.28% Underperform Votes6337.72% Do analysts recommend BCDA or ARAV? BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 1,046.79%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Aravive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in BCDA or ARAV? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryBioCardia and Aravive tied by winning 8 of the 16 factors compared between the two stocks. Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.16%P/E RatioN/A8.5026.7819.65Price / Sales0.42263.11404.49152.18Price / CashN/A65.8538.2534.64Price / BookN/A6.526.964.59Net Income-$76.32M$143.48M$3.23B$248.23M7 Day PerformanceN/A-0.20%-1.24%-1.07%1 Month PerformanceN/A11.63%8.34%3.35%1 Year PerformanceN/A3.21%33.30%13.77% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeBCDABioCardia3.6973 of 5 stars$2.26+4.6%$25.00+1,006.2%-40.3%$11.70M$3K-0.5440Positive NewsShort Interest ↓BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownATHAAthira Pharma2.7053 of 5 stars$0.29-8.8%$13.83+4,752.1%-88.1%$11.13MN/A-0.1040Positive NewsGap DownCLDICalidi Biotherapeutics1.5004 of 5 stars$0.35-1.2%$10.00+2,790.2%N/A$11M$50K0.0038High Trading VolumeAYTUAytu BioPharma1.4895 of 5 stars$1.78flatN/A-32.1%$10.98M$81.66M-1.23160Short Interest ↓NERVMinerva Neurosciences3.3941 of 5 stars$1.56+1.3%$5.00+220.5%-44.9%$10.91MN/A-3.559PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageHCWBHCW Biologics3.4121 of 5 stars$7.21-6.7%$35.00+385.4%-87.8%$10.38M$1.45M-7.2140Analyst DowngradeShort Interest ↓Gap DownDWTXDogwood Therapeutics1.9996 of 5 stars$5.27+1.7%$10.00+89.8%N/A$10.07MN/A-0.805Positive NewsLSBLakeshore Biopharma0.624 of 5 stars$1.07flatN/AN/A$9.96M$672.27M0.00773 Related Companies and Tools Related Companies BCDA Competitors BGXX Competitors ATHA Competitors CLDI Competitors AYTU Competitors NERV Competitors PHXM Competitors HCWB Competitors DWTX Competitors LSB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
